Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis
- 9 February 2009
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 80 (11), 1218-1224
- https://doi.org/10.1136/jnnp.2008.154732
Abstract
Objective: To compare the sample size requirements for a neuroprotection trial with change in cerebral gray matter volume (GMV), white matter volume (WMV) or whole brain parenchymal volume (BPV) as outcome measures in patients with relapsing–remitting multiple sclerosis (RRMS). Methods: Two datasets with longitudinal MRI measures of untreated patients with RRMS (n = 116 and n = 26) and one dataset of treated patients with RRMS (n = 109) were investigated. In each dataset, normalised GMV, normalised WMV and normalised BPV were analysed using a random intercepts and slopes model to estimate the variance components and per cent change. The required sample size to observe a 33%, 50% and 90% reduction in the per cent change was calculated for each dataset using both a constant per cent change for each measurement and the estimated per cent change for each dataset. Results: The per cent change was greatest in GMV but all variance components were smallest in BPV. Using the estimated per cent change, the sample size required in the untreated cohorts was similar for GMV and BPV, and both were lower than WMV. In the treated cohort, the sample size for GMV was the smallest of all measures. Including additional scans reduced the sample size but increasing the length of the trial and clustering scans led to greater reductions. Conclusions: Cerebral GMV may be a viable outcome measure for clinical trials investigating neuroprotection in RRMS patients, especially considering that the treatment effect may be larger on GMV compared with BPV. However, GMV was somewhat limited by increased variability versus BPV.This publication has 27 references indexed in Scilit:
- Mechanisms of Disease: sodium channels and neuroprotection in multiple sclerosis—current statusNature Clinical Practice Neurology, 2008
- Iron in Chronic Brain Disorders: Imaging and Neurotherapeutic ImplicationsNeurotherapeutics, 2007
- Deep grey matter `black T2` on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosisMultiple Sclerosis Journal, 2007
- Imaging correlates of axonal swelling in chronic multiple sclerosis brainsAnnals of Neurology, 2007
- I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophyMultiple Sclerosis Journal, 2007
- Evidence for progressive gray matter loss in patients with relapsing-remitting MSNeurology, 2005
- The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correctionNeuroImage, 2005
- Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosisMultiple Sclerosis Journal, 2004
- Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromesBrain, 2004
- Rating neurologic impairment in multiple sclerosisNeurology, 1983